Jetze Beeksma advises life sciences companies and research institutions on the strategic protection and enforcement of intellectual property in the field of biotechnology and pharmaceuticals.
He works with clients throughout the patent lifecycle, from patentability assessments to drafting and worldwide patent prosecution. Jetze also regularly advises on patent validity and infringement matters, and is frequently involved in high-stakes patent disputes before the EPO, national courts and the Unified Patent Court. This experience informs his strategic advice across the full patent lifecycle. Clients value his responsiveness and his ability to translate complex technology into clear and practical patent strategies. He joined V.O. in 2014
Professional qualifications
European Patent attorney
Dutch Patent Attorney
UPC Representative
Education
MSc, Molecular Biology & Biotechnology, University of Groningen (cum laude)
LLM, Law, University of Groningen (cum laude)
Recognition
Recommended Individual, JUVE Patent
Rising Star, Managing IP
Directory feedback
“Recently, pharmaceutical litigation by patent attorneys such as Jetze Beeksma and Martin Klok for research-based industry has dominated more than in previous years. Both partners are stars in the Dutch patent scene.” (JUVE Patent)
“The life sciences group had an exceptionally strong year thanks to the meteoric rise of Jetze Beeksma, who was lead counsel for the technical aspects of Moderna’s litigation against Pfizer and BioNTech in the Dutch proceedings over mRNA vaccines.” (JUVE Patent)
“We appreciate the team’s high-quality work. They are very responsive and, most of all, easy to work with (Jetze Beeksma).” (Managing IP)
“He is doing a great job on the originator side.” (JUVE Patent)
Can an invention whose manufacture, sale or use is illegal still qualify for patent protection? It is a question that surprises many people, because the answer is less straightforward than you might expect. Under European patent law, illegality does not automatically preclude an invention from being patentable.Continue reading
In G 1/25 (Enlarged Board of Appeal, 3 September 2026), the Enlarged Board of Appeal of the European Patent Office (EPO) decided whether, and on what legal basis, the description must be adapted when the claims are amended. The decision resolves a long-standing divergence in the case law of the Boards of Appeal and builds […]Continue reading
In UPC_CFI_523/2025, Wittenstein SE v Vestas Wind Systems A/S, the Court of First Instance, Central Division (Section Munich), decided on 2 September 2026 how lack of entitlement may operate as a ground for revocation under Article 138(1)(e) EPC. The Court held that it is not sufficient for a claimant to establish rights to only part […]Continue reading
Congress Center Hamburg, Congressplatz, Hamburg, Germany
The annual AIPPI World Congress, held in September or October, is the only time of year when members from around the world come together to discuss current issues in the field of intellectual property.